Avoiding toxicity with lung radiation therapy: An IASLC perspective.
暂无分享,去创建一个
P. Iyengar | C. Faivre-Finn | A. Louie | D. Palma | G. Hanna | J. Belderbos | S. Siva | F. McDonald | P. Samson | N. Bucknell | K. Chua | D. Gómez | D. Gomez
[1] R. Mak,et al. Major adverse cardiac event risk prediction model incorporating baseline cardiac disease, hypertension, and logarithmic left anterior descending coronary artery radiation dose in lung cancer (CHyLL). , 2022, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[2] O. Riesterer,et al. Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (Lung ART): an open-label, randomised, phase 3 trial. , 2021, The Lancet. Oncology.
[3] J. Sonke,et al. Delivered dose-effect analysis of radiation induced rib fractures after thoracic SBRT. , 2021, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[4] James D. Murphy,et al. Radiation Recall Pneumonitis After Treatment With Checkpoint Blockade Immunotherapy: A Case Series and Review of Literature , 2021, Frontiers in Oncology.
[5] B. Yeap,et al. Assessment of a Contralateral Esophagus-Sparing Technique in Locally Advanced Lung Cancer Treated With High-Dose Chemoradiation: A Phase 1 Nonrandomized Clinical Trial. , 2021, JAMA oncology.
[6] B. Solomon,et al. Living with and beyond metastatic non-small cell lung cancer: the survivorship experience for people treated with immunotherapy or targeted therapy , 2021, Journal of Cancer Survivorship.
[7] R. Mak,et al. Mean Heart Dose is an Inadequate Surrogate for Left Anterior Descending Coronary Artery Dose and the Risk of Major Adverse Cardiac Events in Lung Cancer Radiotherapy. , 2021, International journal of radiation oncology, biology, physics.
[8] O. Arrieta,et al. Radiation-induced lung injury: current evidence , 2021, BMC Pulmonary Medicine.
[9] Yi-long Wu,et al. Brief report: Four-year survival with durvalumab after chemoradiotherapy in Stage III NSCLC - an update from the PACIFIC trial. , 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[10] M. V. van Herk,et al. Challenges in the target volume definition of lung cancer radiotherapy , 2020, Translational lung cancer research.
[11] R. Mak,et al. Association of Left Anterior Descending Coronary Artery Radiation Dose With Major Adverse Cardiac Events and Mortality in Patients With Non-Small Cell Lung Cancer. , 2020, JAMA oncology.
[12] M. Aznar,et al. Cardiac Toxicity of Thoracic Radiotherapy: Existing Evidence and Future Directions , 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[13] N. Hardcastle,et al. Single-arm prospective interventional study assessing feasibility of using gallium-68 ventilation and perfusion PET/CT to avoid functional lung in patients with stage III non-small cell lung cancer , 2020, BMJ Open.
[14] W. Ryder,et al. Isotoxic Intensity Modulated Radiation Therapy in Stage III Non-Small Cell Lung Cancer: A Feasibility Study , 2020, International journal of radiation oncology, biology, physics.
[15] B. Jeremic,et al. Radiation-induced lung toxicity – cellular and molecular mechanisms of pathogenesis, management, and literature review , 2020, Radiation Oncology.
[16] Emily Lam,et al. The impact of smoking on adjuvant breast cancer radiation treatment: A systematic review. , 2020, Cancer treatment and research communications.
[17] M. V. van Herk,et al. Radiotherapy-related lymphopenia affects overall survival in patients with lung cancer. , 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[18] J. Welsh,et al. Interaction between lymphopenia, radiotherapy technique, dosimetry, and survival outcomes in lung cancer patients receiving combined immunotherapy and radiotherapy. , 2020, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[19] D. Chang,et al. Second cancer risk after primary cancer treatment with three‐dimensional conformal, intensity‐modulated, or proton beam radiation therapy , 2020, Cancer.
[20] D. Thwaites,et al. Particle therapy toxicity outcomes: A systematic review , 2020, Journal of medical imaging and radiation oncology.
[21] A. Louie,et al. Stereotactic ablative radiotherapy for the comprehensive treatment of 1–3 Oligometastatic tumors (SABR-COMET-3): study protocol for a randomized phase III trial , 2020, BMC Cancer.
[22] P. Illei,et al. Immune-Related Pneumonitis After Chemoradiotherapy and Subsequent Immune Checkpoint Blockade in Unresectable Stage III Non-Small-Cell Lung Cancer. , 2020, Clinical lung cancer.
[23] Saqalgghmnvh Rrdrarlrl,et al. Report of the Chicago Charitable Eye and Ear Infirmary , 1860, The Chicago Medical Journal.
[24] Harry J de Koning,et al. Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial. , 2020, The New England journal of medicine.
[25] C. Benes,et al. Radioresistance of KRAS/TP53‐mutated lung cancer can be overcome by radiation dose escalation or EGFR tyrosine kinase inhibition in vivo , 2020, International journal of cancer.
[26] K. Forster,et al. Long-Term Results of NRG Oncology RTOG 0617: Standard- Versus High-Dose Chemoradiotherapy With or Without Cetuximab for Unresectable Stage III Non-Small-Cell Lung Cancer. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] B. Yaremko,et al. Assessment of precision irradiation in early non-small cell lung cancer and interstitial lung disease (ASPIRE-ILD): study protocol for a phase II trial , 2019, BMC Cancer.
[28] D. de Ruysscher,et al. Radiation-Induced Lung Injury (RILI) , 2019, Front. Oncol..
[29] A. Louie,et al. Is the Importance of Heart Dose Overstated in the Treatment of Non-Small Cell Lung Cancer? A Systematic Review of the Literature. , 2019, International Journal of Radiation Oncology, Biology, Physics.
[30] J. Chang-Claude,et al. Multi-centre technical evaluation of the radiation-induced lymphocyte apoptosis assay as a predictive test for radiotherapy toxicity , 2019, Clinical and translational radiation oncology.
[31] Michael Lock,et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial , 2019, The Lancet.
[32] J. Lee,et al. Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] Tomas Kron,et al. Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial. , 2019, The Lancet. Oncology.
[34] Xiaodong Yang,et al. Trends in the incidence, treatment, and survival of patients with lung cancer in the last four decades , 2019, Cancer management and research.
[35] F. Kong,et al. Chest Wall Toxicity After Stereotactic Body Radiation Therapy: A Pooled Analysis of 57 Studies. , 2017, International journal of radiation oncology, biology, physics.
[36] Ali Kamen,et al. An image-based deep learning framework for individualizing radiotherapy dose. , 2019, The Lancet. Digital health.
[37] E. Yorke,et al. Organs at Risk Considerations for Thoracic Stereotactic Body Radiation Therapy: What Is Safe for Lung Parenchyma? , 2018, International journal of radiation oncology, biology, physics.
[38] D. Planchard,et al. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC , 2018, The New England journal of medicine.
[39] F. de Vathaire,et al. Review of risk factors of secondary cancers among cancer survivors. , 2018, The British journal of radiology.
[40] C. Benes,et al. TP53 mutation status: emerging biomarker for precision radiation medicine? , 2018, Oncoscience.
[41] N. Hardcastle,et al. Functional lung imaging in radiation therapy for lung cancer: A systematic review and meta-analysis. , 2018, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[42] C. Simone,et al. Advances in proton therapy in lung cancer , 2018, Therapeutic advances in respiratory disease.
[43] A. Louie,et al. SUNSET: Stereotactic Radiation for Ultracentral Non-Small-Cell Lung Cancer-A Safety and Efficacy Trial. , 2018, Clinical lung cancer.
[44] D. Landau,et al. Study protocol for the SARON trial: a multicentre, randomised controlled phase III trial comparing the addition of stereotactic ablative radiotherapy and radical radiotherapy with standard chemotherapy alone for oligometastatic non-small cell lung cancer , 2018, BMJ Open.
[45] Tinsu Pan,et al. Patient-reported lung symptoms as an early signal of impending radiation pneumonitis in patients with non-small cell lung cancer treated with chemoradiation: an observational study , 2018, Quality of Life Research.
[46] Steven H. Lin,et al. A systematic review of the influence of radiation-induced lymphopenia on survival outcomes in solid tumors. , 2018, Critical reviews in oncology/hematology.
[47] J. Douillard,et al. Patterns of locoregional failure in locally advanced non-small cell lung cancer treated with definitive conformal radiotherapy: Results from the Gating 2006 trial. , 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[48] R. Salgia,et al. Phase 1 Study of Accelerated Hypofractionated Radiation Therapy With Concurrent Chemotherapy for Stage III Non-Small Cell Lung Cancer: CALGB 31102 (Alliance). , 2015, International journal of radiation oncology, biology, physics.
[49] J. She,et al. Blood-based biomarkers for precision medicine in lung cancer: precision radiation therapy. , 2017, Translational lung cancer research.
[50] M. Socinski,et al. Heart dosimetric analysis of three types of cardiac toxicity in patients treated on dose-escalation trials for Stage III non-small-cell lung cancer. , 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[51] W. Curran,et al. Long-Term Results of RTOG 0617: A Randomized Phase 3 Comparison of Standard Dose Versus High Dose Conformal Chemoradiation Therapy +/- Cetuximab for Stage III NSCLC , 2017 .
[52] J. Sonke,et al. Heart dose associated with overall survival in locally advanced NSCLC patients treated with hypofractionated chemoradiotherapy. , 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[53] A. Bezjak,et al. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial , 2017, The Lancet. Oncology.
[54] Sara Ramella,et al. Local Control and Toxicity of Adaptive Radiotherapy Using Weekly CT Imaging: Results from the LARTIA Trial in Stage III NSCLC , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[55] Paul E Kinahan,et al. Functional lung avoidance and response‐adaptive escalation (FLARE) RT: Multimodality plan dosimetry of a precision radiation oncology strategy , 2017, Medical physics.
[56] M. Janssen-Heijnen,et al. Effects of prehabilitation and rehabilitation including a home-based component on physical fitness, adherence, treatment tolerance, and recovery in patients with non-small cell lung cancer: A systematic review. , 2017, Critical reviews in oncology/hematology.
[57] J. Sonke,et al. Dose to heart substructures is associated with non-cancer death after SBRT in stage I-II NSCLC patients. , 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[58] C. Faivre-Finn,et al. Effect of accurate heart delineation on cardiac dose during the CONVERT trial. , 2017, The British journal of radiology.
[59] A. Berman,et al. Predicted Rate of Secondary Malignancies Following Adjuvant Proton Versus Photon Radiation Therapy for Thymoma. , 2017, International journal of radiation oncology, biology, physics.
[60] R. Thomson,et al. Implementing shared decision making in the NHS: lessons from the MAGIC programme , 2017, British Medical Journal.
[61] Wei Chen,et al. Etoposide and cisplatin versus paclitaxel and carboplatin with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer: a multicenter randomized phase III trial , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[62] P. Xia,et al. A Histologic Basis for the Efficacy of SBRT to the lung , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[63] Jacob G. Scott,et al. A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study. , 2017, The Lancet. Oncology.
[64] M. Socinski,et al. Cardiac Toxicity After Radiotherapy for Stage III Non-Small-Cell Lung Cancer: Pooled Analysis of Dose-Escalation Trials Delivering 70 to 90 Gy. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[65] M. Janssen-Heijnen,et al. Stage III Non-Small Cell Lung Cancer in the elderly: Patient characteristics predictive for tolerance and survival of chemoradiation in daily clinical practice. , 2016, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[66] Markus Alber,et al. Adaptive radiotherapy for advanced lung cancer ensures target coverage and decreases lung dose. , 2016, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[67] R. Govindan,et al. PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[68] Jeffrey V Siebers,et al. Benefits of adaptive radiation therapy in lung cancer as a function of replanning frequency. , 2016, Medical physics.
[69] S. Kabus,et al. The first patient treatment of computed tomography ventilation functional image-guided radiotherapy for lung cancer. , 2016, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[70] G. Sharp,et al. A Contralateral Esophagus-Sparing Technique to Limit Severe Esophagitis Associated With Concurrent High-Dose Radiation and Chemotherapy in Patients With Thoracic Malignancies. , 2015, International journal of radiation oncology, biology, physics.
[71] W. Curran,et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. , 2015, The Lancet. Oncology.
[72] Grace Parraga,et al. Functional lung avoidance for individualized radiotherapy (FLAIR): study protocol for a randomized, double-blind clinical trial , 2014, BMC Cancer.
[73] Pranshu Mohindra,et al. Dose-limiting toxicity after hypofractionated dose-escalated radiotherapy in non-small-cell lung cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[74] J. Sonke,et al. Severe late esophagus toxicity in NSCLC patients treated with IMRT and concurrent chemotherapy. , 2013, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[75] A. Huang,et al. Improved targeting of cancer care for older patients: a systematic review of the utility of comprehensive geriatric assessment. , 2013, Journal of geriatric oncology.
[76] J. Mariani,et al. Cardiac complications of thoracic irradiation. , 2013, Journal of the American College of Cardiology.
[77] Jeffrey D Bradley,et al. Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis. , 2013, International journal of radiation oncology, biology, physics.
[78] V. Servois,et al. Acute Radiation Pneumonitis in Non-small Cell Lung Cancer: Is Respiratory-gated Control Useful? Results of a French Prospective Randomized Study , 2012 .
[79] Damien C Weber,et al. QA makes a clinical trial stronger: evidence-based medicine in radiation therapy. , 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[80] V. Bar-ad,et al. Esophagitis, treatment-related toxicity in non-small cell lung cancer. , 2012, Reviews on recent clinical trials.
[81] H. Thierens,et al. Development of a multicomponent prediction model for acute esophagitis in lung cancer patients receiving chemoradiotherapy. , 2011, International journal of radiation oncology, biology, physics.
[82] C. Gatsonis,et al. Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening , 2012 .
[83] Jose Belderbos,et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[84] Jan-Jakob Sonke,et al. Adaptive radiotherapy for lung cancer. , 2010, Seminars in radiation oncology.
[85] T. Schultheiss,et al. Radiation dose-volume effects in the spinal cord. , 2010, International journal of radiation oncology, biology, physics.
[86] Joseph O. Deasy,et al. Radiation DoseVolume Effects in the Lung , 2010 .
[87] Annette Kopp-Schneider,et al. 4D-CT-based target volume definition in stereotactic radiotherapy of lung tumours: comparison with a conventional technique using individual margins. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[88] David Boulware,et al. A gene expression model of intrinsic tumor radiosensitivity: prediction of response and prognosis after chemoradiation. , 2009, International journal of radiation oncology, biology, physics.
[89] Lech Papiez,et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[90] H. Møller,et al. Radiation-induced malignancies following radiotherapy for breast cancer , 2004, British Journal of Cancer.
[91] Marcel van Herk,et al. Errors and margins in radiotherapy. , 2004, Seminars in radiation oncology.
[92] Steven E Lipshultz,et al. Radiation-associated cardiovascular disease. , 2003, Critical reviews in oncology/hematology.
[93] John D Boice,et al. Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. , 2002, Journal of the National Cancer Institute.
[94] A. R. Marchese,et al. Changes in the proportion of types I and III collagen in the left ventricular wall of patients with post-irradiative pericarditis. , 1996, Cardiovascular surgery.
[95] R Mohan,et al. Dose-volume histograms. , 1991, International journal of radiation oncology, biology, physics.